For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Neuropsychiatric Symptoms and Global Functional Impairment along the Alzheimer’s ContinuumWadsworth L.P.b · Lorius N.a,b · Donovan N.J.a,d · Locascio J.J.b · Rentz D.M.a,b · Johnson K.A.a,c · Sperling R.A.a,b · Marshall G.A.a,b
aCenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Departments of bNeurology and cRadiology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass., and dDepartment of Psychiatry, Cambridge Health Alliance, Cambridge, Mass., USA Corresponding Author
Gad A. Marshall, MD
Center for Alzheimer Research and Treatment
Brigham and Women’s Hospital
221 Longwood Avenue, BL-104H
Boston, MA 02115 (USA)
Tel. +1 617 732 8085, E-Mail email@example.com
Background/Aims: Neuropsychiatric symptoms in Alzheimer’s disease (AD) are highly prevalent. We sought to determine whether neuropsychiatric symptoms were related to global functional impairment at baseline and over a 3-year period in older normal control (NC), mild cognitive impairment (MCI) and mild AD dementia subjects. Methods: Eight hundred and twelve subjects (229 NC, 395 MCI, 188 AD) from the Alzheimer’s Disease Neuroimaging Initiative study underwent cognitive and behavioral assessments over 3 years. Results: Greater hallucinations, anxiety and apathy were associated with greater global functional impairment at baseline, while the presence of hallucinations and apathy at baseline was associated with greater global functional impairment over time across all subjects. The following neuropsychiatric symptoms were not significantly associated with global functioning: delusions, agitation, depression, euphoria, disinhibition, irritability, aberrant motor behaviors, sleep and appetite. Conclusions: These results suggest that increased baseline hallucinations, apathy and anxiety are associated with current and future disease progression in AD.
© 2012 S. Karger AG, Basel